---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-25-000357"
form_type: "8-K"
ticker: "SBFM"
cik: "0001402328"
company_name: "Sunshine Biopharma Inc."
filed_at: "2025-01-15T23:59:59+00:00"
generated_at: "2026-05-28T01:02:07.113045+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Sunshine Biopharma appoints Michel Roy as Chief Commercial Officer

## Summary
- Michel Roy appointed CCO effective Jan 13, 2025; initial base salary of $400,000 CAD annually.
- Severance of $500,000 CAD payable if terminated without cause, plus minimum statutory notice.
- Roy previously led Canadian ops of Shilpa Medicare (2020-2024) and was VP at Intas Pharmaceuticals (2014-2020).
- Responsibilities include overseeing commercial strategy, sales, marketing, and business development.

## SEC filing metadata
- accession: 0001683168-25-000357
- form_type: 8-K
- ticker: SBFM
- cik: 0001402328
- company_name: Sunshine Biopharma Inc.
- filed_at: 2025-01-15T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1402328/000168316825000357/0001683168-25-000357-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1402328/000168316825000357/sunshine_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-25-000357
- JSON: https://secwatch.observer/filing/0001683168-25-000357.json
- Plain text: https://secwatch.observer/filing/0001683168-25-000357.txt

## Key facts
- Executive change
  Michel Roy was appointed as Chief Commercial Officer at Sunshine Biopharma Inc..
  - Action: appointed
  - Role: Chief Commercial Officer
  source text: On January 13, 2025, Sunshine Biopharma Inc. (the “Company”) appointed Mr. Michel Roy as the Company’s Chief Commercial Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1402328/000168316825000357/0001683168-25-000357-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.